Peter Charles Tyler

USPTO Granted Patents = 38 (Patent Applications = 3)

CIPO Patents = 8 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 8)

Average Co-Inventor Count = 3.6

ph-index = 14

Forward Citations = 440(Granted Patents)

Location History:

Northland, NZ (2009 - 2018)
Wellington, NZ (1995 - 2022)

Company Filing History:

22 out of 504

Albert Einstein College of Medicine

patents

19 out of 74

Industrial Research Limited

patents

12 out of 51

Victoria Link Limited

patents

4. 2 out of 117

The University of Liverpool

Alber Einslein College of Medicine

patent

7. 7 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2022

Loading Chart...

38 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11518779 - Inhibitors of DNMT1 as anticancer therapeutic agents (2022-12-06),

2. 11186603 - Heparan sulfate glycomimetic compounds and their pharmaceutical and cosmeceutical uses (2021-11-30),

3. 11186575 - Treatment of helicobacter pylori infections (2021-11-30),

4. 10227351 - Salt and polymorphic forms of (3R,4S)-L-((4-amino-5H-pyrrolo[3,2,-D]pyrimidin-7-yl)methyl)-4(methylthiomethyl)pyrodin-3-ol(MTDIA) (2019-03-12),

5. 9994574 - Salt and polymorphic forms of (3R,4S)-L-((4-amino-5H-pyrrolo[3,2,-d]pyrimidin-7-yl)methyl)-4(methylthiomethyl)pyrodin-3-ol(MTDIA) (2018-06-12),

6. 9957272 - 3-hydroxypyrrolidine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase (2018-05-01),

7. 9879041 - Saccharide dendritic cluster compounds as inhibitors of BACE-1 (2018-01-30),

8. 9828341 - Dendritic core compounds (2017-11-28),

9. 9522159 - [object Object] (2016-12-20),

10. 9493465 - 3-hydroxypyrrolidine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase (2016-11-15),

11. 9315587 - Oligosaccharide compounds (2016-04-19),

12. 9290501 - Methods, assays and compounds for treating bacterial infections by inhibiting methylthioinosine phosphorylase (2016-03-22),

13. 8884000 - Saporin-L1 inhibitors and uses thereof (2014-11-11),

14. 8853224 - Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases (2014-10-07),

15. 8394950 - Analogues of coformycin and their use for treating protozoan parasite infections (2013-03-12),

Title: **Peter Charles Tyler: A Pioneer in Anticancer Therapeutics**

Introduction

Peter Charles Tyler is an innovative inventor based in Wellington, New Zealand. With a remarkable portfolio of 38 patents, he has made significant contributions to the fields of biochemistry and pharmaceutical sciences. His inventions focus on developing treatments for various diseases, showcasing his commitment to advancing medical science.

Latest Patents

Among his latest patents, Tyler has developed inhibitors of DNMT1 as anticancer therapeutic agents. These compounds target DNA methyltransferase 1, an enzyme crucial for maintaining DNA CpG methylation marks in human cells. His invention includes a range of pharmaceutical compositions and methodologies for effectively inhibiting this enzyme. Additionally, he has also worked on methods for treating Helicobacter pylori infections, particularly in patients with peptic ulcers. This patent involves administering inhibitors of 5'-methylthioadenosine nucleosidase, offering new avenues for treatment.

Career Highlights

Tyler's career boasts valuable experiences at prominent institutions such as Industrial Research Limited and Albert Einstein College of Medicine of Yeshiva University. His work has not only led to groundbreaking inventions but also positioned him as an influential figure in the field of cancer research and treatment strategies.

Collaborations

Throughout his career, Peter Charles Tyler has collaborated with notable individuals in the scientific community, including Vern L. Schramm and Richard Hubert Furneaux. These partnerships have been essential in shaping his research endeavors and enhancing the impact of his inventions on medical science.

Conclusion

Peter Charles Tyler exemplifies the spirit of innovation with his extensive patent portfolio and significant contributions to anticancer research. His commitment to developing effective therapeutic agents highlights the importance of collaboration and creativity in driving forward medical advancements. As a distinguished inventor, Tyler continues to inspire future generations of researchers and inventors.

This text is generated by artificial intelligence and may not be accurate.